Literature DB >> 30863564

Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients' treatment.

Concetta Elisa Onesti1,2,3, Pierre Frères2, Guy Jerusalem2,3.   

Abstract

Entities:  

Year:  2019        PMID: 30863564      PMCID: PMC6384391          DOI: 10.21037/jtd.2018.12.47

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  23 in total

1.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.

Authors:  Martin Reck; Rolf Kaiser; Anders Mellemgaard; Jean-Yves Douillard; Sergey Orlov; Maciej Krzakowski; Joachim von Pawel; Maya Gottfried; Igor Bondarenko; Meilin Liao; Claudia-Nanette Gann; José Barrueco; Birgit Gaschler-Markefski; Silvia Novello
Journal:  Lancet Oncol       Date:  2014-01-09       Impact factor: 41.316

Review 4.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Authors:  Lesley Seymour; Jan Bogaerts; Andrea Perrone; Robert Ford; Lawrence H Schwartz; Sumithra Mandrekar; Nancy U Lin; Saskia Litière; Janet Dancey; Alice Chen; F Stephen Hodi; Patrick Therasse; Otto S Hoekstra; Lalitha K Shankar; Jedd D Wolchok; Marcus Ballinger; Caroline Caramella; Elisabeth G E de Vries
Journal:  Lancet Oncol       Date:  2017-03-02       Impact factor: 41.316

5.  Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.

Authors:  Shumei Kato; Aaron Goodman; Vighnesh Walavalkar; Donald A Barkauskas; Andrew Sharabi; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-03-28       Impact factor: 12.531

6.  Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

Authors:  Anna Maria Di Giacomo; Riccardo Danielli; Massimo Guidoboni; Luana Calabrò; Dora Carlucci; Clelia Miracco; Luca Volterrani; Maria Antonietta Mazzei; Maurizio Biagioli; Maresa Altomonte; Michele Maio
Journal:  Cancer Immunol Immunother       Date:  2009-01-13       Impact factor: 6.968

7.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

Review 8.  Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

Authors:  Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal:  Cancer Cell       Date:  2015-12-14       Impact factor: 31.743

9.  Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Authors:  E Saâda-Bouzid; C Defaucheux; A Karabajakian; V P Coloma; V Servois; X Paoletti; C Even; J Fayette; J Guigay; D Loirat; F Peyrade; M Alt; J Gal; C Le Tourneau
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

10.  Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Authors:  J H Lee; G V Long; S Boyd; S Lo; A M Menzies; V Tembe; A Guminski; V Jakrot; R A Scolyer; G J Mann; R F Kefford; M S Carlino; H Rizos
Journal:  Ann Oncol       Date:  2017-05-01       Impact factor: 32.976

View more
  11 in total

1.  Molecular MRI of the Immuno-Metabolic Interplay in a Rabbit Liver Tumor Model: A Biomarker for Resistance Mechanisms in Tumor-targeted Therapy?

Authors:  Lynn Jeanette Savic; Luzie A Doemel; Isabel Theresa Schobert; Ruth Rebecca Montgomery; Nikhil Joshi; John James Walsh; Jessica Santana; Vasily Pekurovsky; Xuchen Zhang; MingDe Lin; Lucas Adam; Annemarie Boustani; James Duncan; Lin Leng; Richard John Bucala; S Nahum Goldberg; Fahmeed Hyder; Daniel Coman; Julius Chapiro
Journal:  Radiology       Date:  2020-07-07       Impact factor: 11.105

Review 2.  CAR-T Cells for the Treatment of Lung Cancer.

Authors:  Luisa Chocarro; Hugo Arasanz; Leticia Fernández-Rubio; Ester Blanco; Miriam Echaide; Ana Bocanegra; Lucía Teijeira; Maider Garnica; Idoia Morilla; Maite Martínez-Aguillo; Sergio Piñeiro-Hermida; Pablo Ramos; Juan José Lasarte; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Life (Basel)       Date:  2022-04-08

3.  Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.

Authors:  Casey Quinn; Louis P Garrison; Anja K Pownell; Michael B Atkins; Gérard de Pouvourville; Kevin Harrington; Paolo Antonio Ascierto; Phil McEwan; Samuel Wagner; John Borrill; Elise Wu
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

4.  Hyperprogression in PDL1 Expressive, Recurrent Gastroesophageal-junction Adenocarcinoma After Pembrolizumab.

Authors:  Shashank Sama; Matthew J Hadfield; Nerea Lopetegui Lia; James Vredenburgh
Journal:  Cureus       Date:  2019-06-07

Review 5.  Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?

Authors:  Luisa Chocarro de Erauso; Miren Zuazo; Hugo Arasanz; Ana Bocanegra; Carlos Hernandez; Gonzalo Fernandez; Maria Jesus Garcia-Granda; Ester Blanco; Ruth Vera; Grazyna Kochan; David Escors
Journal:  Front Pharmacol       Date:  2020-04-07       Impact factor: 5.810

6.  Salvage Immunotherapy With Pembrolizumab in Patients Hospitalized for Life-Threatening Complications of NSCLC.

Authors:  Ferréol Roborel de Climens; Christos Chouaid; Claire Poulet; Vincent Leroy; Luc Stoven; Alexis Benjamin Cortot; Xavier Dhalluin; Clément Gauvain
Journal:  JTO Clin Res Rep       Date:  2021-01-19

7.  Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.

Authors:  Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Taihei Nishiyama; Li-Tzong Chen; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2021-03-20       Impact factor: 7.370

Review 8.  Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model.

Authors:  Mikolaj Kocikowski; Katarzyna Dziubek; Maciej Parys
Journal:  Cancers (Basel)       Date:  2020-03-27       Impact factor: 6.639

9.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

10.  Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients.

Authors:  Anna Grenda; Paweł Krawczyk; Justyna Błach; Izabela Chmielewska; Tomasz Kubiatowski; Stanisław Kieszko; Kamila Wojas-Krawczyk; Tomasz Kucharczyk; Bożena Jarosz; Iwona Paśnik; Małgorzata Borowiec-Bar; Małgorzata Frąk; Robert Kieszko; Michał Szczyrek; Katarzyna Reszka; Kinga Krukowska; Agnieszka Kolak; Sławomir Mańdziuk; Dariusz Kowalski; Marek Sawicki; Daria Świniuch; Elżbieta Starosławska; Rodryg Ramlau; Justyna Szumiło; Maciej Krzakowski; Janusz Milanowski
Journal:  Front Oncol       Date:  2021-02-08       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.